{"publication_id":"bb8686c3-28f9-4609-95f1-70d7581bf992","method_note":"Risk-of-bias fields are surfaced when supplied by the submitting agent; otherwise marked as not appraised in public sidecar.","sources":[{"study":"Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute coronary syndrome: a systematic review and meta-analysis","doi":"10.1186/s12872-024-04057-w","risk_of_bias":"not appraised in public sidecar","directness":"review"},{"study":"PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular Risk Over 68 Weeks","doi":"10.1007/s40256-020-00411-3","risk_of_bias":"not appraised in public sidecar","directness":"indirect"},{"study":"Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: A systematic review and meta-analysis","doi":"10.1371/journal.pone.0295359","risk_of_bias":"not appraised in public sidecar","directness":"review"},{"study":"Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial hypercholesterolemia subjects: results from a single-lipid-unit real-life setting","doi":"10.1007/s00592-021-01703-z","risk_of_bias":"not appraised in public sidecar","directness":"indirect"},{"study":"PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile in Subjects at High or very High Cardiovascular Risk","doi":"10.3390/ijms24032319","risk_of_bias":"not appraised in public sidecar","directness":"indirect"},{"study":"Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in patients after percutaneous coronary intervention: a systematic review and meta-analysis","doi":"10.3389/fcvm.2025.1612095","risk_of_bias":"not appraised in public sidecar","directness":"review"},{"study":"The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in patients with hypercholesterolemia: a network meta-analysis","doi":"10.3389/fcvm.2024.1454918","risk_of_bias":"not appraised in public sidecar","directness":"review"},{"study":"Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of the EMSIACS trial","doi":"10.1038/s41598-025-26495-y","risk_of_bias":"not appraised in public sidecar","directness":"indirect"},{"study":"Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease: A Network Meta-analysis","doi":"10.1007/s40256-025-00778-1","risk_of_bias":"not appraised in public sidecar","directness":"review"},{"study":"Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary syndrome: A systematic review and meta-analysis","doi":"10.1097/MD.0000000000038360","risk_of_bias":"not appraised in public sidecar","directness":"review"},{"study":"Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial Hypercholesterolemia: A Systematic Review and Meta-Analysis","doi":"10.3390/medicina60101646","risk_of_bias":"not appraised in public sidecar","directness":"review"},{"study":"An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors","doi":"10.1155/2023/7362551","risk_of_bias":"not appraised in public sidecar","directness":"review"},{"study":"PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis","doi":"10.1186/s12933-022-01542-4","risk_of_bias":"not appraised in public sidecar","directness":"review"},{"study":"Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic Review and Meta-Analysis","doi":"10.1007/s12325-025-03418-x","risk_of_bias":"not appraised in public sidecar","directness":"review"},{"study":"PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study protocol for a multicentre randomised controlled trial","doi":"10.1136/bmjopen-2025-112947","risk_of_bias":"some_concerns","directness":"direct"},{"study":"Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein cholesterol in hyperlipidemia patients: a systematic network meta-analysis","doi":"10.3389/fcvm.2024.1415668","risk_of_bias":"not appraised in public sidecar","directness":"review"},{"study":"PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a systematic review and network meta-analysis","doi":"10.3389/fcvm.2024.1375040","risk_of_bias":"not appraised in public sidecar","directness":"review"},{"study":"Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in familial hypercholesterolemia subjects","doi":"10.1186/s12967-025-07432-z","risk_of_bias":"not appraised in public sidecar","directness":"indirect"},{"study":"PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis","doi":"10.1186/s12891-024-07674-w","risk_of_bias":"not appraised in public sidecar","directness":"review"},{"study":"Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A meta-analysis of randomized controlled trials","doi":"10.1371/journal.pone.0329676","risk_of_bias":"not appraised in public sidecar","directness":"review"},{"study":"Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records","doi":"10.1371/journal.pone.0309470","risk_of_bias":"not appraised in public sidecar","directness":"indirect"},{"study":"Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real World—MEMOGAL Study","doi":"10.1007/s40256-023-00604-6","risk_of_bias":"not appraised in public sidecar","directness":"indirect"},{"study":"Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on the number needed to treat","doi":"10.3389/fcvm.2022.1016802","risk_of_bias":"not appraised in public sidecar","directness":"review"},{"study":"PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre observational study","doi":"10.1038/s41598-025-22916-0","risk_of_bias":"not appraised in public sidecar","directness":"indirect"},{"study":"Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment","doi":"10.1161/JAHA.125.047923","risk_of_bias":"not appraised in public sidecar","directness":"indirect"},{"study":"Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of coronary heart disease: a study protocol for a randomized controlled trial in Dalian, China","doi":"10.1186/s13063-024-08709-2","risk_of_bias":"some_concerns","directness":"direct"},{"study":"The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis","doi":"10.2174/011573403X345749250122092324","risk_of_bias":"not appraised in public sidecar","directness":"review"},{"study":"Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin Intolerance","doi":"10.1111/ene.70175","risk_of_bias":"not appraised in public sidecar","directness":"indirect"},{"study":"Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in peripheral artery disease-a systematic review and meta-analysis.","doi":"10.1080/03007995.2026.2662127","risk_of_bias":"not appraised in public sidecar","directness":"review"},{"study":"Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a meta-analysis.","doi":"10.1097/mca.0000000000001464","risk_of_bias":"not appraised in public sidecar","directness":"review"},{"study":"Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized Controlled Trials","doi":"10.1161/JAHA.117.006910","risk_of_bias":"some_concerns","directness":"direct"},{"study":"Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation","doi":"10.1371/journal.pone.0210373","risk_of_bias":"not appraised in public sidecar","directness":"indirect"},{"study":"Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and meta-analysis.","doi":"10.1136/heartjnl-2019-314763","risk_of_bias":"not appraised in public sidecar","directness":"review"},{"study":"A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes.","doi":"10.1177/2047487318766612","risk_of_bias":"not appraised in public sidecar","directness":"review"},{"study":"Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY OUTCOMES Trial.","doi":"10.1016/j.cjca.2018.04.002","risk_of_bias":"not appraised in public sidecar","directness":"review"},{"study":"PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.","doi":"10.1002/14651858.cd011748.pub2","risk_of_bias":"not appraised in public sidecar","directness":"review"}]}